Cellebrite DI (NASDAQ:CLBT) Rating Lowered to “Hold” at Wall Street Zen

Cellebrite DI (NASDAQ:CLBT) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday.

Several other research firms have also issued reports on CLBT. Needham & Company LLC reduced their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, August 14th. Lake Street Capital dropped their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Weiss Ratings reissued a “sell (d+)” rating on shares of Cellebrite DI in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. lifted their price objective on Cellebrite DI from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Wednesday, September 24th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Cellebrite DI Trading Up 0.9%

CLBT stock traded up $0.14 during midday trading on Friday, hitting $15.40. The stock had a trading volume of 1,346,159 shares, compared to its average volume of 1,637,106. The firm has a market cap of $3.69 billion, a P/E ratio of -20.26, a price-to-earnings-growth ratio of 3.16 and a beta of 1.28. Cellebrite DI has a 1-year low of $13.10 and a 1-year high of $26.30. The business has a fifty day moving average price of $17.76 and a two-hundred day moving average price of $16.78.

Cellebrite DI (NASDAQ:CLBT) last issued its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.01. Cellebrite DI had a positive return on equity of 23.92% and a negative net margin of 34.56%.The business had revenue of $113.28 million during the quarter, compared to the consensus estimate of $112.33 million. During the same period in the previous year, the company posted $0.10 earnings per share. The firm’s revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts anticipate that Cellebrite DI will post 0.3 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of CLBT. T. Rowe Price Investment Management Inc. purchased a new stake in Cellebrite DI in the first quarter worth about $60,939,000. Invesco Ltd. boosted its stake in Cellebrite DI by 122.1% during the first quarter. Invesco Ltd. now owns 3,296,079 shares of the company’s stock worth $64,043,000 after buying an additional 1,811,757 shares during the period. Voss Capital LP grew its holdings in Cellebrite DI by 34.0% during the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after purchasing an additional 1,306,398 shares during the last quarter. Phoenix Financial Ltd. grew its stake in shares of Cellebrite DI by 153.5% during the second quarter. Phoenix Financial Ltd. now owns 2,014,617 shares of the company’s stock valued at $32,232,000 after buying an additional 1,219,958 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in Cellebrite DI in the 1st quarter worth about $22,428,000. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.